Diagnostic Accuracy of (18)F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence.
Diagnostic Accuracy of (18)F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence.
复制标题
（18）F-PSMA-1007 PET/CT成像的诊断精度，用于原发性和生化复发中前列腺癌的淋巴结分期。
DOI：
10.2967/jnumed.120.246363
复制
发表时间：
2021-03
期刊：
影响因子：
--
通讯作者：
Giesel FL
中科院分区：
文献类型：
--
作者：
Sprute K;Kramer V;Koerber SA;Meneses M;Fernandez R;Soza-Ried C;Eiber M;Weber WA;Rauscher I;Rahbar K;Schaefers M;Watabe T;Uemura M;Naka S;Nonomura N;Hatazawa J;Schwab C;Schütz V;Hohenfellner M;Holland-Letz T;Debus J;Kratochwil C;Amaral H;Choyke PL;Haberkorn U;Sandoval C;Giesel FL
前列腺特异性膜抗原（PSMA）-配体PET/CT对前列腺癌患者进行初步分期或确定最终治疗后的复发部位。根据临床结果，18F-PSMA-1007是一种有前途的PSMA PET示踪剂，但缺乏详细的组织学证实。研究方法：96例前列腺癌患者接受了18F-PSMA-1007 PET/CT，随后进行了根治性前列腺切除术和淋巴结切除术或挽救性淋巴结切除术。回顾性分析PSMA PET阳性淋巴结的组织学表现。进行了基于病变和基于患者的分析，比较了组织病理学上所有阳性病变和仅大于3 mm的病变。结果如下：在这些患者中，90.6%的患者在初次治疗前接受了18F-PSMA-1007 PET/CT分期，而9.4%的患者接受了生化复发成像。在34.4%的队列中，成像时存在阳性淋巴结。96例患者共清扫了1，746个淋巴结。18F-PSMA-1007 PET检测大于3 mm的阳性淋巴结的基于病变的灵敏度为81.7%，特异性为99.6%，阳性预测值为92.4%，阴性预测值为98.9%。在分析所有恶性淋巴结（无论大小）时，总体灵敏度、特异性、阳性预测值、基于病灶分析的阴性预测值分别为71.2%、99.5%、91.3%和97.9%。以患者为基础的分析显示，大于3 mm的淋巴结的敏感性为85.9%，特异性为99.5%。结论：18 F-PSMA-1007 PET/CT可靠地检测恶性淋巴结，并具有超过99%的特异性为淋巴结转移。
Prostate-specific membrane antigen (PSMA)–ligand PET/CT is performed on patients with prostate cancer to stage the disease initially or to identify sites of recurrence after definitive therapy. On the basis of clinical results, 18F-PSMA-1007 is a promising PSMA PET tracer, but detailed histologic confirmation has been lacking. Methods: Ninety-six patients with prostate cancer underwent 18F-PSMA-1007 PET/CT followed by either radical prostatectomy with lymphadenectomy or salvage lymphadenectomy. The histologic findings of PSMA PET–positive nodes were analyzed retrospectively. A lesion-based and patient-based analysis was performed comparing all positive lesions and only lesions larger than 3 mm on histopathology. Results: Of the patients, 90.6% received 18F-PSMA-1007 PET/CT for staging before the primary treatment, whereas 9.4% underwent imaging for biochemical recurrence. In 34.4% of the cohort, positive lymph nodes were present on imaging. In total, 1,746 lymph nodes were dissected in 96 patients. 18F-PSMA-1007 PET had a lesion-based sensitivity of 81.7%, a specificity of 99.6%, a positive predictive value of 92.4%, and a negative predictive value of 98.9% for detecting positive lymph nodes larger than 3 mm. In the analysis of all malignant nodes regardless of size, the overall sensitivity, specificity, positive predictive value, and negative predictive value on lesion-based analysis were 71.2%, 99.5%, 91.3%, and 97.9%, respectively. The patient-based analysis showed a sensitivity of 85.9% and a specificity of 99.5% for lymph nodes larger than 3 mm. Conclusion: 18F-PSMA-1007 PET/CT reliably detects malignant lymph nodes and has an exceptional specificity of more than 99% for nodal metastases.
登录
查看更多内容
DOI：
10.1007/s00259-019-04361-0
发表时间：
2019-09-01
影响因子：
9.1
作者：
Abufaraj, Mohammad;Grubmueller, Bernhard;Hartenbach, Markus
通讯作者：
Hartenbach, Markus
影响因子：
6.6
作者：
Jilg, Cordula A.;Schultze-Seemann, Wolfgang;Rischke, H. Christian
通讯作者：
Rischke, H. Christian
使用 68Ga 标记的 PSMA 配体 HBED-CC 进行 PET/CT 成像诊断复发性前列腺癌的价值
DOI：
10.1007/s00259-014-2949-6
发表时间：
2015-02-01
影响因子：
9.1
作者：
Afshar-Oromieh, Ali;Avtzi, Eleni;Haberkorn, Uwe
通讯作者：
Haberkorn, Uwe
影响因子：
9.3
作者：
Kesch, Claudia;Vinsensia, Maria;Giesel, Frederik L.
通讯作者：
Giesel, Frederik L.
影响因子：
6.6
作者：
Maurer, Tobias;Gschwend, Juergen E.;Eiber, Matthias
通讯作者：
Eiber, Matthias